FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Xiang, Zuo Lin ^a   Erasmus, Jeremy ^a   Komaki, Ritsuko ^a   Cox, James D ^a   Chang, Joe Y ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Non small cell lung cancer; PET CT imaging; Prognostic factors; Proton therapy; Standardized uptake value

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTON THERAPY; RADIATION DOSE; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; PROTON THERAPY; RADIOPHARMACEUTICALS;

EID: 84865322776     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-144     Document Type: Article

References (22)

1. Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103:1452-1460. 10.1093/jnci/djr325, 21903745.
2. Bradley JD, Bae K, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA, Michalski JM, Gore E, Choy H. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. J Clin Oncol 2010, 28:2475-2480. 10.1200/JCO.2009.27.1205, 2881726, 20368547.
3. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, Mohan R, Komaki R, Cox JD. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 65:1087-1096. 10.1016/j.ijrobp.2006.01.052, 16682145.
4. Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, Cox JD, Chang JY. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 2010, 77:357-366. 10.1016/j.ijrobp.2009.04.028, 2868090, 19660879.
5. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 2011, Epub ahead of print.
6. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, Fidler V, Pruim J, Groen HJ. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000, 343:254-261. 10.1056/NEJM200007273430404, 10911007.
7. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003, 348:2500-2507. 10.1056/NEJMoa022136, 12815135.
8. Everitt S, Herschtal A, Callahan J, Plumridge N, Ball D, Kron T, Schneider-Kolsky M, Binns D, Hicks RJ, MacManus M. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. Cancer 2010, 116:5030-5037. 10.1002/cncr.25392, 20623786.
9. Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 2009, 30:4-5.
10. Fleckenstein J, Hellwig D, Kremp S, Grgic A, Gröschel A, Kirsch CM, Nestle U, Rübe C. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial. Int J Radiat Oncol Biol Phys 2011, 81(4):e283-e289. 10.1016/j.ijrobp.2011.01.020, 21470782.
11. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, Schwaiger M. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003, 21:2651-2657. 10.1200/JCO.2003.12.004, 12860940.
12. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, et al. [18 F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005, 23:1136-1143. 10.1200/JCO.2005.06.129, 15718309.
13. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, Ball DL. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003, 21:1285-1292. 10.1200/JCO.2003.07.054, 12663716.
14. Hicks RJ, Mac Manus MP, Matthews JP, Hogg A, Binns D, Rischin D, Ball DL, Peters LJ. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004, 60:412-418. 10.1016/j.ijrobp.2004.03.036, 15380574.
15. Chang JY, Dong L, Liu H, Starkschall G, Balter P, Mohan R, Liao Z, Cox JD, Komaki R. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol 2008, 3:177-186. 10.1097/JTO.0b013e3181622bdd, 18303441.
16. Moyers MF, Miller DW, Bush DA, Slater JD. Methodologies and tools for proton beam design for lung tumors. Int J Radiat Oncol Biol Phys 2001, 49:1429-1438. 10.1016/S0360-3016(00)01555-8, 11286851.
17. Kang Y, Zhang X, Chang JY, Wang H, Wei X, Liao Z, Komaki R, Cox JD, Balter PA, Liu H, et al. 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys 2007, 67:906-914. 10.1016/j.ijrobp.2006.10.045, 17293240.
18. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002, 35:179-187. 10.1016/S0169-5002(01)00332-4, 11804691.
19. Abramyuk A, Tokalov S, Zöphel K, Koch A, Szluha Lazanyi K, Gillham C, Herrmann T, Abolmaali N. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?. Radiother Oncol 2009, 91:399-404. 10.1016/j.radonc.2009.01.003, 19168248.
20. Klopp AH, Chang JY, Tucker SL, Sulman EP, Balter PA, Liu HH, Bucci MK, Macapinlac HA, Komaki R, Cox JD. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 2007, 69:1409-1416. 10.1016/j.ijrobp.2007.05.085, 17904303.
21. Kim YS, Lee MK, Kim SJ, Kim IJ, Kim YK, Jo WS, Park SK. Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (stage III and IV) non-small cell lung cancer. Neoplasma 2010, 57:241-246. 10.4149/neo_2010_03_241, 20353275.
22. Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J. Prognostic stratification of stage IIIAN2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 2008, 26:1128-1134. 10.1200/JCO.2007.13.9550, 18309948.